JASON RODGERS: Open Payments
NPI 1568600492 · TACOMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,080 in 90 payments from 15 companies in 2025. Trend: 2023 $460 · 2024 $1,424 · 2025 $2,080
Food & beverage: $2,080
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $689 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $360 |
| Phathom Pharmaceuticals, Inc. | 12 | $280 |
| Janssen Biotech, Inc. | 16 | $269 |
| Regeneron Healthcare Solutions, Inc. | 3 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $70 |
| Aimmune Therapeutics, Inc. | 3 | $64 |
| Lilly USA, LLC | 2 | $53 |
| Madrigal Pharmaceuticals | 1 | $45 |
| Celltrion USA Inc. | 2 | $40 |
Products named: LINZESS, VOQUEZNA, ENTYVIO, TREMFYA, CREON, DUPIXENT, SKYRIZI, XIFAXAN.
Industry payments across WA — which companies pay providers there.
